SNAP Biosciences
SNAP Biosciences is developing a universal immune receptor platform, SNAP-CAR, that enables engineered T and NK cells to be directed by already existing antibody-based therapeutics.
ONCOLEADER | COMPANY PROFILES
Emerging Biotech
These profiles are built to help emerging oncology companies clearly communicate their science, strategy, and story.
Each one is created by the Oncoleader team in collaboration with the company to serve as a public-facing, investor- and partner-friendly narrative asset.
Encelta AG
Encelta AG is a swiss-based biotech developing a universal TCR-T cell platform designed to augment CD3-targeting T cell engagers.
Jabez Biosciences
Jabez Biosciences is a US-Based biotech developing a potential best-in-class small molecule inhibitor of DHODH that they’re using to augment existing pipelines.
Infinova Biosciences
Infinova Biosciences is developing a first-in-class cell-based drug delivery platform for the treatment of hard-to-reach solid tumors.
